OMER Insider Trading

Insider Trading Chart
Insider Trading History
Frequently Asked Questions
About

Insider Ownership Percentage: 10.90%

Insider Buying (Last 12 Months): $40,500.00

Insider Selling (Last 12 Months): $32,300.00

Omeros Insider Trading History Chart

Omeros Share Price & Price History

^$2.57

▼ -0.02 (-0.77%)

As of 12/8/2023 09:57 PM ET

Days: 30 | 90 | 365

Lithium Discovery So BIG You Can't Miss it, Even From Space

From Financial Alphas | Ad

With the green energy transition well underway, lithium demand is rapidly outpacing projected supply. While companies frantically search for new sources of this critical metal, one small company is sitting on a massive claim in North America - So big in fact that it can clearly be seen from space!

Free Investor Report Reveals Ambitious Plan To Mee

Omeros Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
11/17/2023	Gregory A. Demopulos	CEO	Buy	15,000	$1.68	$25,200.00	123,945
11/15/2023	Peter A Md Demopulos	Director	Buy	10,000	$1.53	$15,300.00	208,516
5/22/2023	Arnold C. Hanish	Director	Sell	5,000	$6.46	$32,300.00	35,067
6/17/2021	Gregory A. Demopulos	CEO	Sell	36,857	$14.90	$549,169.30	2,063,842
6/15/2021	Gregory A. Demopulos	CEO	Sell	36,856	$15.02	$553,577.12	2,063,842
4/8/2021	Gregory A. Demopulos	CEO	Sell	72,613	$17.84	$1,295,415.92	2,064,393
2/22/2021	Michael A. Jacobsen	CAO	Sell	8,100	$23.28	$188,568.00	24,000
2/19/2021	Michael A. Jacobsen	CAO	Sell	10,000	$22.64	$226,400.00	24,000
2/10/2021	Michael A. Jacobsen	CAO	Sell	1,900	$22.49	$42,731.00	15,900
1/19/2021	Michael A. Jacobsen	CAO	Sell	9,500	$19.95	$189,525.00	4,000
1/13/2021	Thomas J Cable	Director	Sell	5,000	$16.97	$84,850.00	40,067

Is This The Most Overlooked Gold Investment Strategy of 2024?

From Edge On The Street | Ad

There is little debate on the potential of gold in the next year and decade. The real issue becomes - what's the best gold investment strategy today? Some investors are opting for a unique "royalty" alternative that outshines other options like holding gold bullion or investing in volatile mining stocks.

Read this stunning report on a little-known gold

SEC Filings (Institutional Ownership Changes) for Omeros (NASDAQ:OMER)

41.70% of Omeros stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

Omeros Institutional Trading History

Reporting Date	Hedge Fund	Shares Held	Market Value	% of Portfolio	Quarterly Change in Shares	Ownership in Company
11/24/2023	Deutsche Bank AG	29,460	$86K	0.0%	-16.1%	0.047%
11/21/2023	Walleye Trading LLC	17,266	$50K	0.0%	N/A	0.027%
11/21/2023	Comerica Bank	25,000	$73K	0.0%	N/A	0.040%
11/16/2023	Tudor Investment Corp Et Al	40,059	$0.12M	0.0%	-26.2%	0.064%
11/15/2023	Royal Bank of Canada	2,055,899	$6M	0.0%	-82.9%	3.270%
11/15/2023	AQR Capital Management LLC	35,565	$0.10M	0.0%	N/A	0.057%
11/14/2023	Ancora Advisors LLC	210,023	$0.61M	0.0%	+23.1%	0.334%
11/14/2023	Nomura Holdings Inc.	445,482	$1.30M	0.0%	-28.3%	0.709%
11/14/2023	California State Teachers Retirement System	13,433	$39K	0.0%	-33.7%	0.021%
11/14/2023	O Shaughnessy Asset Management LLC	17,098	$50K	0.0%	N/A	0.027%
11/13/2023	Northern Trust Corp	546,043	$1.59M	0.0%	-1.4%	0.869%
11/13/2023	Stifel Financial Corp	2,027,917	$5.92M	0.0%	-1.4%	3.226%
11/13/2023	Invesco Ltd.	66,545	$0.19M	0.0%	+101.8%	0.106%
11/9/2023	UBS Group AG	590,642	$1.73M	0.0%	+1.6%	0.940%
11/8/2023	Charles Schwab Investment Management Inc.	490,968	$1.43M	0.0%	+5.3%	0.781%
11/7/2023	Barclays PLC	45,629	$0.13M	0.0%	+51.2%	0.073%
11/1/2023	Jacob Asset Management of New York LLC	55,168	$0.16M	0.2%	-31.2%	0.088%
10/13/2023	SG Americas Securities LLC	19,105	$56K	0.0%	N/A	0.030%
9/21/2023	Barclays PLC	30,173	$0.16M	0.0%	-62.5%	0.048%
9/12/2023	Farther Finance Advisors LLC	6,000	$33K	0.0%	N/A	0.010%
8/21/2023	California State Teachers Retirement System	20,251	$0.11M	0.0%	N/A	0.032%
8/21/2023	Osaic Holdings Inc.	4,898	$27K	0.0%	-68.6%	0.008%
8/16/2023	Nuveen Asset Management LLC	181,632	$0.99M	0.0%	N/A	0.289%
8/15/2023	Alliancebernstein L.P.	11,700	$64K	0.0%	N/A	0.019%
8/15/2023	Goldman Sachs Group Inc.	140,119	$0.76M	0.0%	-41.4%	0.223%
8/15/2023	Stifel Financial Corp	2,056,835	$11.19M	0.0%	+4.7%	3.272%
8/14/2023	Tudor Investment Corp Et Al	54,295	$0.30M	0.0%	-50.4%	0.086%
8/14/2023	State Street Corp	1,139,199	$6.20M	0.0%	+344.7%	1.812%
8/14/2023	Nuveen Asset Management LLC	181,632	$0.99M	0.0%	N/A	0.289%
8/14/2023	Cerity Partners LLC	22,850	$0.12M	0.0%	+44.2%	0.036%
8/11/2023	BlackRock Inc.	4,154,952	$22.60M	0.0%	+258.0%	6.613%
8/11/2023	Ameritas Investment Partners Inc.	5,027	$27K	0.0%	N/A	0.008%
8/11/2023	State Board of Administration of Florida Retirement System	17,280	$94K	0.0%	N/A	0.028%
8/11/2023	The Manufacturers Life Insurance Company	25,138	$0.14M	0.0%	N/A	0.040%
8/11/2023	Franklin Resources Inc.	29,095	$0.16M	0.0%	N/A	0.046%
8/11/2023	Geode Capital Management LLC	1,253,711	$6.82M	0.0%	+98.4%	1.995%
8/11/2023	JPMorgan Chase & Co.	49,173	$0.27M	0.0%	+2,473.2%	0.078%
8/11/2023	Northern Trust Corp	553,605	$3.01M	0.0%	+256.5%	0.881%
8/10/2023	MetLife Investment Management LLC	32,266	$0.18M	0.0%	N/A	0.051%
8/10/2023	Osaic Holdings Inc.	4,898	$27K	0.0%	-68.6%	0.008%
8/10/2023	ProShare Advisors LLC	11,983	$65K	0.0%	N/A	0.019%
8/10/2023	Jacob Asset Management of New York LLC	80,168	$0.44M	0.5%	-16.6%	0.128%
8/10/2023	Mirae Asset Global Investments Co. Ltd.	32,148	$0.18M	0.0%	N/A	0.051%
8/10/2023	Cetera Advisors LLC	88,365	$0.48M	0.0%	N/A	0.141%
8/10/2023	Charles Schwab Investment Management Inc.	466,079	$2.54M	0.0%	+38.6%	0.742%
8/10/2023	Citigroup Inc.	19,197	$0.10M	0.0%	-71.8%	0.031%
8/9/2023	BNP Paribas Arbitrage SNC	15,874	$86K	0.0%	+2,791.4%	0.025%
8/8/2023	Rhumbline Advisers	91,240	$0.50M	0.0%	N/A	0.145%
8/4/2023	American International Group Inc.	29,302	$0.16M	0.0%	N/A	0.047%
8/3/2023	Barclays PLC	30,173	$0.16M	0.0%	-62.5%	0.048%
8/3/2023	Bank of New York Mellon Corp	202,595	$1.10M	0.0%	+280.3%	0.322%
8/2/2023	Bank of Montreal Can	563,297	$3.40M	0.0%	N/A	0.897%
7/25/2023	Raymond James & Associates	44,718	$0.24M	0.0%	-25.2%	0.071%
7/13/2023	Cambridge Investment Research Advisors Inc.	47,430	$0.26M	0.0%	-13.1%	0.075%
7/6/2023	Apella Capital LLC	14,288	$78K	0.0%	N/A	0.023%
5/16/2023	Ancora Advisors LLC	233,517	$1.09M	0.0%	-27.9%	0.372%
5/16/2023	Jane Street Group LLC	296,910	$1.38M	0.0%	N/A	0.473%
5/16/2023	State Street Corp	256,174	$1.19M	0.0%	-8.1%	0.408%
5/16/2023	Squarepoint Ops LLC	89,176	$0.42M	0.0%	N/A	0.142%
5/16/2023	Geode Capital Management LLC	631,892	$2.94M	0.0%	+4.3%	1.006%
5/16/2023	Balyasny Asset Management L.P.	16,902	$79K	0.0%	N/A	0.027%
5/15/2023	Nomura Holdings Inc.	503,529	$2.34M	0.0%	-42.3%	0.801%
5/15/2023	Two Sigma Advisers LP	77,700	$0.36M	0.0%	-62.5%	0.124%
5/15/2023	Two Sigma Investments LP	59,800	$0.28M	0.0%	-70.0%	0.095%
5/15/2023	Deutsche Bank AG	20,488	$95K	0.0%	-59.4%	0.033%
5/15/2023	Price T Rowe Associates Inc. MD	22,200	$0.10M	0.0%	-27.5%	0.035%
5/12/2023	Stifel Financial Corp	1,963,620	$9.13M	0.0%	+34.8%	3.125%
5/12/2023	BlackRock Inc.	1,160,484	$5.40M	0.0%	+1.9%	1.847%
5/12/2023	Bank of America Corp DE	88,894	$0.41M	0.0%	-66.4%	0.141%
5/12/2023	HRT Financial LP	58,336	$0.27M	0.0%	N/A	0.093%
5/12/2023	UBS Group AG	522,873	$2.43M	0.0%	-20.0%	0.832%
5/12/2023	Charles Schwab Investment Management Inc.	336,281	$1.56M	0.0%	+7.6%	0.535%
5/12/2023	HighTower Advisors LLC	58,339	$0.27M	0.0%	+11.5%	0.093%
5/11/2023	Jacob Asset Management of New York LLC	96,168	$0.45M	0.5%	+11.6%	0.153%
5/11/2023	ExodusPoint Capital Management LP	11,600	$54K	0.0%	N/A	0.018%
5/11/2023	Citigroup Inc.	68,032	$0.32M	0.0%	+8,910.9%	0.108%
5/9/2023	Bank of New York Mellon Corp	53,278	$0.25M	0.0%	+90.6%	0.085%
5/8/2023	Brighton Jones LLC	54,517	$0.25M	0.0%	-12.5%	0.087%
5/4/2023	Barclays PLC	80,406	$0.37M	0.0%	+167.5%	0.128%
5/4/2023	Cypress Capital Group	50,000	$0.23M	0.0%	-9.1%	0.080%
5/1/2023	Sheaff Brock Investment Advisors LLC	60,125	$0.28M	0.0%	-4.8%	0.096%
4/14/2023	Raymond James & Associates	59,818	$0.28M	0.0%	-58.5%	0.095%
2/15/2023	CI Private Wealth LLC	642,978	$1.45M	0.0%	N/A	1.025%
2/15/2023	Cerity Partners LLC	15,850	$36K	0.0%	-51.0%	0.025%
2/15/2023	Virtu Financial LLC	34,855	$79K	0.0%	N/A	0.056%
2/15/2023	Millennium Management LLC	353,392	$0.80M	0.0%	-30.1%	0.563%
2/15/2023	Morgan Stanley	197,877	$0.45M	0.0%	-46.6%	0.315%
2/15/2023	Man Group plc	41,295	$93K	0.0%	+185.7%	0.066%
2/15/2023	Ancora Advisors LLC	324,017	$0.73M	0.0%	+121.7%	0.517%
2/14/2023	Price T Rowe Associates Inc. MD	30,600	$69K	0.0%	+73.9%	0.049%
2/14/2023	Marshall Wace LLP	80,172	$0.18M	0.0%	-34.3%	0.128%
2/14/2023	Two Sigma Investments LP	199,237	$0.45M	0.0%	+102.9%	0.318%
2/13/2023	Charles Schwab Investment Management Inc.	312,409	$0.71M	0.0%	+1.4%	0.498%
2/13/2023	Deutsche Bank AG	50,488	$0.11M	0.0%	-9.0%	0.080%
2/13/2023	Barclays PLC	30,057	$68K	0.0%	+732.1%	0.048%
2/13/2023	Credit Suisse AG	28,836	$65K	0.0%	-51.9%	0.046%
2/13/2023	Geode Capital Management LLC	605,812	$1.37M	0.0%	+1.2%	0.966%
2/10/2023	Bank of America Corp DE	264,361	$0.60M	0.0%	+25.5%	0.421%
2/8/2023	Cambridge Investment Research Advisors Inc.	55,087	$0.12M	0.0%	+46.9%	0.088%
2/1/2023	Bank of Montreal Can	563,095	$1.53M	0.0%	-0.7%	0.898%

Data available starting January 2016

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting inflammation, complement-mediated diseases, cancers, and addictive and compulsive disorders. The company's clinical programs include Narsoplimab (OMS721/MASP-2) that has completed pivotal studies for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (HSCT-TMA); that is in Phase III clinical trial for immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19. It also develops OMS1029 that is in phase I clinical trials for long-acting second-generation antibody targeting lectin pathway disorders; OMS906 that is in phase Ib clinical trials for Paroxysmal nocturnal hemoglobinuria, complement 3 glomerulopathy, and other alternative pathway disorders; OMS527 that is in phase I clinical trials for addictions and compulsive disorders, and movement disorders; and OMS405 that is in phase II clinical trials for opioid and nicotine addiction. In addition, the company develops MASP-2-small-molecule inhibitors for the treatment of aHUS, HSCT-TMA, and age-related macular degeneration; GPR174 inhibitors and chimeric antigen receptor T-Cell and adoptive T-Cell therapies for various cancers; and G protein-coupled receptors for treating immunologic, immuno-oncologic, metabolic, CNS, cardiovascular, musculoskeletal, and other disorders. Omeros Corporation was incorporated in 1994 and is headquartered in Seattle, Washington.

Today's Range

Now: $2.57

$2.50

$2.64

50 Day Range

MA: $1.84

$1.08

$2.95

52 Week Range

Now: $2.57

$0.92

$7.80

Volume

353,300 shs

Average Volume

718,413 shs

Market Capitalization

$161.56 million

P/E Ratio

8.03

Dividend Yield

N/A

Beta

1.31

Who are the company insiders with the largest holdings of Omeros?: Omeros' top insider shareholders include:
Peter A Md Demopulos (Director)
Gregory A Md Demopulos (CEO)
Arnold C Hanish (Director)
Learn More about top insider investors at Omeros.
Who are the major institutional investors of Omeros?: Omeros' top institutional investors include:
Royal Bank of Canada — 3.27%
Stifel Financial Corp — 3.23%
UBS Group AG — 0.94%
Northern Trust Corp — 0.87%
Charles Schwab Investment Management Inc. — 0.78%
Nomura Holdings Inc. — 0.71%
Learn More about top institutional investors of Omeros stock.
Which institutional investors are selling Omeros stock?: Within the last quarter, OMER stock was sold by these institutional investors:
Royal Bank of Canada
Nomura Holdings Inc.
Stifel Financial Corp
Jacob Asset Management of New York LLC
Tudor Investment Corp Et Al
Northern Trust Corp
California State Teachers Retirement System
Deutsche Bank AG
Which institutional investors are buying Omeros stock?: Within the previous quarter, OMER stock was purchased by institutional investors including:
Group One Trading L.P.
Ancora Advisors LLC
AQR Capital Management LLC
Invesco Ltd.
Walleye Capital LLC
Comerica Bank
Charles Schwab Investment Management Inc.
SG Americas Securities LLC
In the previous year, these company insiders have bought Omeros stock:
Peter A Md Demopulos (Director)
Gregory A Md Demopulos (CEO)
Learn More investors buying Omeros stock.